The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | GLORA trial: lisaftoclax plus BTKi in previously treated CLL
In this video, Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, introduces the GLORA trial (NCT06104566). This Phase III study will investigate whether adding lisaftoclax to a BTK inhibitor (BTKi) improves outcomes in patients with previously treated chronic lymphocytic leukemia (CLL) and residual disease after prolonged BTKi treatment. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Lisaftoclax is a new BCL2 inhibitor that has a very different pharmacokinetic profile compared to venetoclax. In particular, it’s got a very short half-life and a high level of Cmax, which basically allows it to kill CLL cells quickly, but then not linger in the body and cause tumor lysis syndrome. And so from the early development of lisaftoclax, it was actually developed with a rapid ramp up over five days...
Lisaftoclax is a new BCL2 inhibitor that has a very different pharmacokinetic profile compared to venetoclax. In particular, it’s got a very short half-life and a high level of Cmax, which basically allows it to kill CLL cells quickly, but then not linger in the body and cause tumor lysis syndrome. And so from the early development of lisaftoclax, it was actually developed with a rapid ramp up over five days. And in the early phase data, combining lisaftoclax with acalabrutinib looked very good in terms of high rates of response. And so that early study led to the design of the GLORA trial, which we’re presenting as a trials in progress abstract here at EHA. And really this is a study where we’re taking patients already on acalabrutinib and we’re adding lisaftoclax to see if that provides additional PFS benefit compared to just continuing on acalabrutinib in the control arm. And so, you know, this study is ongoing, it’s actively recruiting, but hopefully will help us to answer the question of whether this kind of doublet based therapy is better than a single agent BTK inhibitor in the relapsed population. And because lisaftoclax has the favorable ramp up with a five-day ramp up, it may have some logistical advantages over venetoclax which has the five-week ramp up.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
